Korsana Biosciences (KRSA) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed Pacira BioSciences (PCRX) over the past year, gaining 90.0% versus a gain of 55.4%. Over five years, PCRX leads with a -31.6% price change compared with -91.1% for KRSA. Korsana Biosciences is the larger company by market cap ($1.58 billion vs $1.45 billion), about 1.1 times the size.
Pacira BioSciences converts more of its revenue into profit, with a net margin of 1.0% versus -170.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | PCRX |
|---|---|---|
| Share price | $34.75 | $36.32 |
| Market cap | $1.58B | $1.45B |
| 1-day change | +3.70% | -0.21% |
| YTD return | +276.94% | +40.61% |
| 1-year return | +89.97% | +55.45% |
| 5-year return | -91.10% | -31.60% |
| P/E ratio (TTM) | — | 103.76 |
| Forward P/E | — | 10.50 |
| EPS (TTM) | $-7.07 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.07M | $726.41M |
| Revenue growth (YoY) | +3.70% | +3.63% |
| Net income (latest FY) | $-3.53M | $7.03M |
| Gross margin | — | 79.39% |
| Operating margin | -239.78% | 2.64% |
| Net margin | -170.11% | 0.97% |
| 52-week high | $59.36 | $36.46 |
| 52-week low | $7.19 | $18.80 |
| Distance from 52-week high | -41.46% | -0.40% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +26.62% | -17.09% |
| Average volume | 32.06K | 1.03M |
| Shares outstanding | 45.54M | 39.91M |
| Employees | 19 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed PCRX by 34.5 percentage points over the past year.
- Pacira BioSciences is more profitable, keeping 1.0 cents of every revenue dollar as net income versus -170.1 cents for Korsana Biosciences.
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
KRSA vs PCRX FAQ
Which is bigger, Korsana Biosciences or Pacira BioSciences?
Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.58B compared with $1.45B for Pacira BioSciences (PCRX).
Which stock has performed better over the past year, KRSA or PCRX?
KRSA returned +89.97% over the past 12 months, compared with +55.45% for PCRX (price return, excluding dividends). Past performance does not predict future results.
Are Korsana Biosciences and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.